Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 6/20 | 0.55 |
| ▸ | FNTB | P49356 | 6/20 | 0.55 |
| ▸ | PGGT1B | P53609 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30051152 | 0.92 | FNTA (0.59) | FNTAFNTBPGGT1BKMT2ALTA4H | |
| SCHEMBL30051184 | 0.92 | FNTA (0.52) | FNTAFNTBPGGT1BLTA4H | |
| SCHEMBL30051449 | 0.90 | FNTA (0.62) | FNTAFNTBPGGT1BKMT2ALTA4H | |
| SCHEMBL30051904 | 0.88 | MME (0.57) | — | |
| SCHEMBL18907573 | 0.87 | BACE1 (0.54) | — | |
| SCHEMBL30051273 | 0.87 | FNTA (0.63) | FNTAFNTBPGGT1BKMT2ALTA4H | |
| SCHEMBL3052110 | 0.87 | CTSD (0.57) | KMT2ALTA4H | |
| SCHEMBL3052108 | 0.87 | CTSD (0.57) | KMT2ALTA4H | |
| SCHEMBL31590754 | 0.86 | MME (0.52) | KMT2A | |
| SCHEMBL30052583 | 0.86 | FNTA (0.57) | FNTAFNTBPGGT1BKMT2ALTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| CN-120519539-A | Sturgeon ovary active peptide with function of resisting ovary aging and preparation method thereof | 厦门元之道生物科技有限公司 | 2025-08-22 | — | — | CN | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | FNTA 734/4885FNTB 479/4885PGGT1B 1338/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | FNTA 776/4885FNTB 452/4885PGGT1B 1883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.